Elan Corporation

Pharmaceutical company

7/26/2008 20:16 ET

Site Map | Contact Us | Search:

Elan News: 2006

1st November 2006

Elan to Present at the Cowen and Company 7th Annual Global Health Care Conference

25th October 2006

Elan Reports Third Quarter 2006 Financial Results

24th October 2006

TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week

9th October 2006

Elan Announces Webcast of Third Quarter 2006 Financial Results

6th October 2006

New Pharmacoeconomic Data on TYSABRI® Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis

4th October 2006

Health Canada Grants Approval of TYSABRI(TM) (natalizumab) for the Treatment of Multiple Sclerosis Following Priority Review

29th September 2006

New Data Presented at ECTRIMS Congress Show TYSABRI® Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years

28th September 2006

New Data on TYSABRI® Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis

27th September 2006

Elan and Transition Therapeutics Inc. Announce Global Collaboration to Develop and Commercialize Alzheimer's Disease Drug AZD-103

1st August 2006

Elan Reports Second Quarter 2006 Financial Results

24th July 2006

Biogen Idec and Elan Announce Availability of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis

6th July 2006

Elan Signs License Agreement with Abbott for Elan's Proprietary NanoCrystal(R) Technology; To Develop a Single Fixed-Dose Combination of TriCor(R) and Crestor(R) for High Cholesterol Patients

5th July 2006

Elan Announces Webcast of Second Quarter 2006 Financial Results

29th June 2006

TYSABRI® Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis

5th June 2006

FDA Approves the Reintroduction of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis

26th May 2006

Elan Announces the Appointment of a New Board Director

25th May 2006

Elan Holds Its AGM, All Resolutions Passed

18th May 2006

Elan Announces Resignation of Board Director

4th May 2006

Elan Reports First Quarter 2006 Financial Results

28th April 2006

CHMP Issues Positive Opinion for TYSABRI® as a Treatment for Relapsing-Remitting Multiple Sclerosis

11th April 2006

Elan Announces Dates for Upcoming Corporate Events

6th April 2006

New Data on TYSABRI® Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis

31st March 2006

Elan Announces Filing of 20-F and Annual Report for Year Ended December 31, 2005

29th March 2006

Biogen Idec and Elan Announce Re-Initiation of TYSABRI® Clinical Trial Dosing in Multiple Sclerosis

22nd March 2006

Biogen Idec and Elan Announce That FDA Will Extend Regulatory Review Period for the Reintroduction of TYSABRI® for Multiple Sclerosis

20th March 2006

Elan Closes Sale of Rights to Prialt In Europe to Eisai

8th March 2006

FDA Advisory Committee Unanimously Recommends Reintroduction of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis

1st March 2006

TYSABRI® Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine; TYSABRI Currently Under Review with U.S. and European Regulatory Authorities

1st March 2006

Institute for the Study of Aging and Elan Pharmaceuticals Announce Winners of New Alzheimer's Disease Drug Discovery Award Program

1st March 2006

Elan Announces Webcast of Presentation at the S.G. Cowen 26th Annual Healthcare Conference

28th February 2006

Elan Announces the Suspension of Trading of Its Shares Commencing March 7, 2006 For Up to Two Days; Suspension of Trading Due to Two Day FDA Advisory Committee Meeting to Review Tysabri

15th February 2006

TYSABRI® Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in MS

9th February 2006

Elan to Sell Rights to Prialt in Europe to Eisai

31st January 2006

Elan Reports Fourth Quarter and Full-Year 2005 Financial Results

30th January 2006

Elan Announces Webcast of Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

23rd January 2006

Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI® for the Treatment of Multiple Sclerosis

13th January 2006

Elan Announces Webcast of Fourth Quarter and Full Year 2005 Financial Results

10th January 2006

Elan and EntreMed Execute License Agreement for Proprietary NanoCrystal® Technology

Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use